RH has previously mentioned that PYC intended to provide the opportunity to access ongoing treatment for those who had participated in the SAD program as a matter of mutual obligation.
This latest approval supports the collection of data which no doubt PYC would consider valuable in terms of being clinically recognized, because maybe PYC think it works pretty darn good., and maybe the patients also share that optimism, which would probably underscore their reasoning to continue treatment.
Ann: Extension of RP11 Single Dose Study Into Multiple Dose Study, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.025(2.11%) |
Mkt cap ! $676.5M | |||
| Open | High | Low | Value | Volume |
| $1.19 | $1.20 | $1.16 | $45.30K | 38.23K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4346 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 563 | 1 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |